Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
96 hedge funds and large institutions have $153M invested in Poseida Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 13 closing their positions.
1,282% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $88K
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 93 → 96 (+3)
0.48% more ownership
Funds ownership: 54.74% → 55.22% (+0.48%)
1% less capital invested
Capital invested by funds: $155M → $153M (-$1.56M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.8M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.48M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.33M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.09M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$843K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$7.66M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$2.15M |
| 3 |
AI
Atom Investors
Austin,
Texas
|
-$1.16M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$358K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$310K |
PSTX Hedge Fund Activity: Q3 2024 in Review
96 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2024, worth a combined $153M — down 1% from $155M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PSTX positions and 13 closed out — a net gain of 3 holders — while 36 added to existing stakes and 21 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.8M. The largest seller was Boxer Capital, cutting an estimated $7.66M.
- 96 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2024, up from 93 in Q2 2024.
- Funds reported $153M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2024, down 1% quarter-over-quarter.
- 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2024 and 13 closed out, a net change of +3 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2024 was Millennium Management, an estimated $4.8M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2024 was Boxer Capital, an estimated $7.66M sold.
Based on aggregated 13F filings for Q3 2024.